Global Cystic Fibrosis Market that predicts the growth of the market with a substantial 13.8% CAGR during the forecast period of 2016-2022. The MRFR report also asserts that the cystic fibrosis market is a likely to achieve USD 1, 192.2 Mn valuation by 2022 end.
The inherited chronic malaise namely cystic fibrosis (CF) causes accumulation of thick and sticky mucus in lungs and digestive system that leads to obstruction of the natural system which causes infection. Caused due to mutation in cystic fibrosis transmembrane conductance regulator (CFTR) protein gene, the disease has symptoms which include continuous respiratory infection, fatty stool, and loss of appetite. The treatment for cystic fibrosis is likely to compel the pharmaceuticals in manufacturing more effective drugs, thereby creating immense opportunity for the key players operating in the market to invest in research and developmental activities.
Cystic fibrosis hinders all endocrinal hormone activities which can sometimes lead to infertility in men. Hence, early diagnosis is crucial. Medical advancements are expected to bring positive results in boosting the cystic fibrosis diagnostics techniques. These are important factors which are anticipated to promulgate market growth. The diagnosis and treatment of cystic fibrosis are expensive. This is an expected retarder of the global cystic fibrosis market.
Key Players
- Vertex Pharmaceuticals
- F. Hoffmann-La Roche
- AbbVie
- Gilead Sciences
- Novartis
- Genentech
- Pharmaxis
- Chiesi Pharmaceutics
- Forest Laboratories and more.
Segmental Overview
The global cystic fibrosis market segmentation by MRFR is based on treatment method.
It offers a comprehensive study on the market. The treatment method is further narrowed down to medication, devices, and other treatments. The medication segment is anticipated to hold the maximum market share. This medication segment is estimated to grow with an impressive 14% CAGR during the upcoming years of 2016-2022.
Regional Analysis
MRFR in its report mentions a detailed regional analysis that gives a clear picture of the regional market drivers and restraints. Geographically, the cystic fibrosis therapeutics market
study is segmented into North America, Asia Pacific, Europe, and Rest-of-the-World (RoW).
The highest market share is likely to be owned by North America, with a valuation estimated to grow to USD 531 million by 2022 end. The region boasting of its technological advancements and medical infrastructure is impelling the cystic fibrosis market.
The European cystic fibrosis market is expected to attain an astounding 14.1% CAGR in the forthcoming years owing to the European governmental healthcare benefits.
The Asia Pacific region to experience a progressive cystic fibrosis market. However, in countries like China and Japan the occurrence rate of cystic fibrosis is relatively lower compared to the other countries of APAC. The economic backlog and deploring medical infrastructure in the Middle East Asia and Africa is impeding the cystic fibrosis market growth.
To know more About Related Report with Top Companies at
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
No comments:
Post a Comment